Governing Biobanks: Challenges and Perspectives Chih-Hsing Ho, PhD Centre for Medical Ethics and Law The University of Hong Kong

Slides:



Advertisements
Similar presentations
4 th Meeting of the EC International Dialogue on Bioethics Copenhagen, June 19 th, 2012 Large research and medical databases in clinical and research multi-centred.
Advertisements

Personalized Medicine in California Kathryn Lowell, Deputy Secretary for Life Sciences and Health Systems February, 2009.
Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.
Supporting National e-Health Roadmaps WHO-ITU-WB joint effort WSIS C7 e-Health Facilitation Meeting 13 th May 2010 Hani Eskandar ICT Applications, ITU.
BIOETHICS: THE SUBJECT, PURPOSE AND OBJECTIVES OF THE HEALTH CARE SYSTEM. BIOETHICS OF BIOMEDICAL EXPERIMENTS. INTERNATIONAL DOCUMENTS ON BIOETHICS AND.
Wrapup. NHGRI strategic plan What does the NIH think genomics should be for the next 10 years? [Nature, Feb. 2011]
The Imperial College Tissue Bank A searchable catalogue for tissues, research projects and data outcomes Prof Gerry Thomas - Dept. Surgery & Cancer The.
XX Conference Seattle 2005 Consent and other legalities MedLawconsult.
Dr. Almut Nebel Dept. of Human Genetics University of the Witwatersrand Johannesburg South Africa Significance of SNPs for human disease.
CHANGING DYNAMICS OF SCIENCE AND TECHNOLOGY – FINLAND IN A GLOBAL PERSPECTIVE DSocSc. Karoliina Snell Department of Social Research/Sociology.
Protecting Participants in a Global Research Community Dr. Jane Kaye University of Oxford, UK.
Hss4303b – Intro to Epidemiology March 18, 2010 – Molecular & Genetic Epidemiology.
Irish Health Research: Collaboration and Partnership HSE Regional Library & Information Health Research Seminar Dr. Steevens’ Hospital 11th February 2011.
BIG DATA AND THE HEALTHCARE REVOLUTION FORD+SSPG 2014.
The National Academies’ Board on Life Sciences Dr. Frances Sharples Director National Research Council National Research Council.
The Nuffield Council on Bioethics Report : The collection, linking and use of data in biomedical research and health care: ethical issues. Martin Richards.
What are the challenges for translation? -Views from Japan and Asia
REG set up: first steps… Alison Chisholm 7.40 am – 7:45 am.
Georgia Wiesner, MD CREC June 20, GATACAATGCATCATATG TATCAGATGCAATATATC ATTGTATCATGTATCATG TATCATGTATCATGTATC ATGTATCATGTCTCCAGA TGCTATGGATCTTATGTA.
Different Models in Governance: National Biobanks in A Comparative Perspective Dr. Chih-hsing Ho Academia Sinica, Taiwan
Data Management Development and Implementation: an example from the UK SLA Conference, Boston, June 2015 Geraldine Clement-Stoneham Knowledge and Information.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
Workshop on Health Examination Surveys (HES) Legal and ethical issues Susanna Conti, M. Kanieff, G. Rago Istituto Superiore di Sanità (ISS) (National Public.
Criteria for Centres of Expertise for Rare Diseases in the EU following EUCERD Recommendations RARECARENet Project: Consensus meeting on.
Epigenome 1. 2 Background: GWAS Genome-Wide Association Studies 3.
Social Science, Public Engagement and Genetic Databases: Lessons from Generation Scotland Sarah Cunningham-Burley and Gill Haddow University of Edinburgh.
Genetic advances will only be acceptable if their application is carried out ethically, with due regard to autonomy, justice, education and the beliefs.
Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain Barriers and Challenges in Rare Diseases Research Centre.
Perspectives on the Sharing of Research Materials and Data Reid Adler Founder and Principal, Practical Innovation Strategy Washington, DC Presentation.
Future Use of Stored Samples & Data and the NIH Policy on GWAS and dbGaP NIAID/DAIDS Dione Washington, M.S. -- ProPEP Sudha Srinivasan, Ph.D.-- TRP Tanisha.
Implications for the Use of Tissue in Research P. Pearl O’Rourke, MD Partners HealthCare Boston, MA.
Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.
Access to Personalised Medicine for PDAC patients STSM of the application of an EU-index for barriers Denis Horgan (EAPM) & Angela Brand (IPHG) on behalf.
POLICY DILEMMAS IN GENOMICS AND INTERNATIONAL HEALTH POLICY Elettra Ronchi, PhD
Genetic Databases International Collaboration and Secondary Uses Pr Bartha Maria Knoppers Canada Research Chair in Law and Medicine Genetics and Society.
The Value of Tissue Banks to Drug and Dx Developers Barbara L. Handelin, Ph.D. Conflicts of Interest, Privacy/Confidentiality, and Tissue Repositories:
Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.
Policy level The policy and legislation development process in practice (politicians and scientists are involved) differs from the ideal model (politicians,
Send correspondence to: Bartha Maria Knoppers Chair of Interim Board Centre de recherche en Droit Public Université de Montréal.
David Carr The Wellcome Trust Data management and sharing: the Wellcome Trust’s approach Economic & Social Data Service conference.
Human Genome Project Daniel Ospina Joaquín Llano.
Discussion points from the Science|Business Executive Forum UCL, 5 November Technology 2. Money 3. People 4. Global Trends.
Vaccinomics: social and science systems in transition Farah Huzair Innogen, The Open University.
Barriers and Tools to the Present and Future of Population Genetics Pr Bartha Maria Knoppers Canada Research Chair in Law and Medicine HGM 2006.
GENOMIC RESEARCH: INFORMED CONSENT. Genomics- a branch of genetics that sequences DNA to analyze the structure and function of genomes (the complete set.
Biobanks for research. Ethical and regulatory aspects in human biological samples collections in France Christine NOIVILLE CNRS / Paris 1 University.
The Patient Perspective on Tissue and Tissue Banking Judy Perotti May 3, 2004.
Public Population Projects in Genomics International Working Groups Working Meeting September th, 2005, Hinxton, UK.
TISSUE REPOSITORIES: THE COMMON RULE and THE HIPAA PRIVACY RULE Mark A. Rothstein, J.D. Herbert F. Boehl Chair of Law and Medicine Director, Institute.
SSHRC - ERA - SAGE Workshop Research on the Ethical, Legal and Societal Aspects of Human Genomics: North America Denise Avard PhD Director of Research.
Rachel Liao, PhD Coordinator of the Clinical Working Group and the BRCA Challenge demonstration project for the Global Alliance for Genomics and Health.
European Life Sciences Infrastructure for Biological Information ELIXIR and Identity Management 2 nd Workshop on Federated Identity.
D4FF55A0-6B6F BF422A9BA9 Present by: Xiao Chen On December 7, 2015.
The Human Genome Project
Ethics in Clinical Genetics and Genomics Key Knowledge Year 4 Medical Ethics and Law Thread Course, The Ethox Centre, University of Oxford.
Steps for the Integration of Traditional Medicine in the National Health Care Delivery System 18 TH ICASA Special Session on Traditional Medicine 1 st.
Systemic change by streamlined innovation: personalised medicine Novembre 8, 2013.
The Concept The format of BBMRI should be a distributed hub structure in which the hubs coordinate activities, including collection, exchange and analysis.
“Translational research includes two areas of translation. One (T1) is the process of applying discoveries generated during research in the laboratory,
Direct-to-Consumer Genetic Testing: Outputs from the EASAC-FEAM Working Group Martina Cornel VU University Medical Center, Amsterdam.
Medical and Health research in Norway – in brief Director Mari K. Nes 22 June 2006.
Universal Patients’ Rights Association UPRA Decreasing Violation of Patients’ Rights (in the northern part of Cyprus) Rome, 4 of March, 2016.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
Moiz Bakhiet, MD, PhD, Professor and Chairman
TITIN ANDRI WIHASTUTI SCHOOL OF NURSING FACULTY OF MEDICINE
SSHRC - ERA - SAGE Workshop Research on the Ethical, Legal and Societal Aspects of Human Genomics: North America Denise Avard PhD Director of Research.
Research on human biological materials: Lithuanian perspective
Finland, a Global Testbed for Personalized Cancer Research?
Data Access and Stewardship
In Argentina Ana Palmero Legal and Research Ethics Advisor
Presentation transcript:

Governing Biobanks: Challenges and Perspectives Chih-Hsing Ho, PhD Centre for Medical Ethics and Law The University of Hong Kong

“ Organic Bank Account ” To safeguard people ’ s most valuable assets. Rather than depositing money in a personal bank account, it is a repository for people to put in their biomaterials - blood, tissue samples and DNA - in order to earn medical interest some later day in the form of new knowledge and therapies for diseases. (TIME, March 2009)

What does this organic bank look like in reality….?

What does the term “biobank” refer to?

Different Names?  “ genetic databases ” ?  “ biosample repositories ” ?  “ tissue banks ” ?  Collections of human biological materials (samples) + information linkage (data)

OECD Guidelines on Human Biobanks and Genetic Research Databases (2009) structured resources that can be used for the purpose of genetic research, and which include: (a) human biological materials and/or information generated from their analysis; and (b) extensive associated information

Different Types of Biobanks  Taking into consideration the biobanks’ nature, purpose and scope  Sampling: Disease-oriented vs. Population-based biobanks  Business models: commercial vs. non-commercial biobanks  Funding: public vs. private biobanks  Scale: large vs. small (regional) biobanks

Types of Samples & Data Stored (source: Biobanks in Europe, European Commission IPTS, 2010) Types of Materials Stored Types of Data Collected and Stored

Biobank Composition and Purpose (source: Biobanks in Europe, European Commission IPTS, 2010) OwnershipResearch Models

Common Features of Biobanks  Have an ongoing and open-ended nature, namely involving unspecified research in the future that challenges the traditional practice of informed consent.  The banked samples and data need to remain potentially re-identifiable  Have a common good focus, more concerned with the public benefit future generations than with the individual benefit of participants themselves.

Why do we need biobanks?

We need larger sample sizes to support in depth sequencing of large cohorts…

Comprehensive biobanking is gradually maturing..

The way of sample handling (and storage) has improved significantly over the last few decades Before (1970s) Now (2009)

We need biobanks..  To Provide larger sample sizes, accurate DNA concentration and better DNA quality for genomics research  Genomics studies often require sample aggregation from multiple biobanks  Biobanks now emerging as powerful tools in post-genome translational research

Purposes & Application  To find out the causes of diseases, namely to find out the interaction between genetic factors underlying common complex diseases (such as asthma, diabetes, and heart disease), which are caused by a combination of genetic variants and environment factors rather than by individual genes.  Translate biomedical research into diagnostic and therapeutic applications through pharmacogenomics to achieve personalised medicine and improve public health.

Driving Forces: the Completion of the Human Genome Project (HGP)

From Genetics to Genomics  The information coming from the HGP makes possible the study of human genome, namely the entirety of human hereditary information.  The focus of genomics was no longer on single genes or its disorders but on interactions of those genes with each other and with the environment as well.

The Low-cost sequencing.. “$1,000 Genome’ is not a question whether it is possible, but when it will be realized. It is unimaginable only 4 years ago.” (Nature, 2007)

Personalised Medicine “In a handful of years, your doctor may be able to run a computer analysis of your personal genome to get a detailed profile of your health prospects.” (Newsweek 15 Oct 2007)

GWA Studies  A new method for scientists to strategically search genetic makers that involves rapidly scanning SNPs across the complete set of human genomes to find genetic variations associated with a particular disease.  SNPs- single nucleotide polymorphisms- the most common type of genetic variation in individual bases that can be used as makers to locate and identify genes in DNA sequences.

What does it mean if a human genome sequence costs less than $1,000?

Personalised Medicine Reactive medical treatment  Clinical diagnosis and treatment was based on patients’ symptoms and their medical and family history.  Medication in clinics started only after the symptoms appeared. Proactive medical treatment  The idea of customisation of medical treatment in healthcare  All medical decisions and treatment, including preventive and therapeutic care being tailored to adapt to each individual’s particular genetic makeup.

The changing landscape of post-genome science means  Biobanks and collections becoming bigger  Biobanking becoming a specialist and centralised infrastructure (core facility)  Better quality samples and automated tracking  Collaborative biobank networks for international sharing and harmonisation

Biobanking as a Global Phenomenon - Europe (Iceland, the UK, Sweden, Norway, Estonia, Germany, Spain, Italy), - The United States and Canada - East Asia: Taiwan Biobank, China Gene Bank, China Guangzhou Cohort, Biobank Japan - South East Asia: Singapore Bio-Bank (established in 2002, closed in June 2011 (cost around USD 1 million a year to process about 10,000 samples)

Biobank Networking: International Infrastructure for Harmonisation  P3G: Public Population Project in Genomics, an international consortium aims to build a network for sharing and harmonization of governance framework for the population genomics community across the globe.  BBMRI: a pan-European Biobanking and Bimolecular Resources Research Infrastructure covers 30 countries, including 280 associated organizations, most of which are biobank of various types. Aims to provide a sustainable legal framework to benefit European research in life sciences.

BBMRI Infrastructure

International framework supporting networking among independent population-based biobanks (Source: Biobanks in Europe: Prospects for Harmonisation and Networking, 2010)

P3G Sample and Data Access Policies (Core elements) Conditions of Use:  Compliance with original consents and applicable laws and institutional policies  Access granted for a limited time period (e.g., 6 months or a year), after which the recipient must reapply  Primary data must not be patented  Informing the resource of issues related to data integrity as applicable

Biobank Dilemmas:  Privacy, Confidentiality (Data Security) vs. Data Sharing  Broad Consent vs. Specific Consent  Networking vs. Harmonisation  Feedback vs. Right not to know  Access policies and procedures

Legal and Regulation Challenges  Self-governance (IRB/EGC) or Legislations (Biobank Act)  Variation in applicable laws and regulations in different regions and countries  Lack of transparent access policies and procedures  How to set up a suitable governance framework & responsible stewardship maintaining public trust of biobanks

Why are biobanks controversial? (social challenges)  Genetic exceptionalism & Stigmitisation  Privacy and Surveillance  Fears of privatisation and commercialisation (commercial companies ‘owning’ the genetic heritage of a population)

Different Layers of Consent (Source: Hansson et al) Blanket Consent Consent to Biomedical Research Consent to Research on Specific Disease Consent to a Specific Study

Consent and Privacy  Individual consent? Group consent?  How to define groups?  Who can represent the groups to give consent?  Confidentiality: anonymous; coding; double-coding?  Privacy: autonomy to decide how to use genetic information

Property and Commodification  Human tissue: gifts or commodities  Human tissue and genetic information have been transformed into useful resources of biovalue.  A gift model implies a tendency to avoid the recognition of participants as stakeholders and the rearrangement of entitlements for a share of profits

An “upstream ethics”  Strong provisions on “consent & privacy”, but weak provisions on “access & ownership.”  The consent mechanism may satisfy the general expectation of good ethics at the expense of substantive deliberation of the rearrangement of rights and benefits related to biobanks.  Confidentiality: narrow view of privacy

Public Engagement in Biobanks  A crucial challenge is the question of how to link biobanks with the general public and society.  Treating patients and participants as biobank stakeholders rather than only donors (gift givers).  The perception of biobanks in society as key resource for the advancement of heath care in the welfare state.  Trust and transparency: gaining legitimacy for biobanks

Future Direction of Biobanking  Provide a baseline for operating standards on which to build as the state of the science evolves (National Cancer Institute, USA)  Network development for sample and data sharing (P3G, BBMRI)  Harmonise policies and procedures for biobanks  Public engagement is considered the key to achieve good outcomes in biobank governance  Redistribution of benefits and power in Biobanks

Thank you for your attention!